Benzhydryl Compounds

• 

  Subject Areas on Research

  • A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. 
  • A validated chiral HPLC method for the enantiomeric separation of tolterodine tartarate. 
  • Activation of metabotropic glutamate receptor 7 in spinal cord inhibits pain and hyperalgesia in a novel formalin model in sheep. 
  • An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. 
  • Analysis of bisphenol A diglycidyl ether (BADGE) and its hydrolytic metabolites in biological specimens by high-performance liquid chromatography and tandem mass spectrometry. 
  • Applications and societal benefits of plastics. 
  • Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. 
  • Assessment of brain activity during memory encoding in a narcolepsy patient on and off modafinil using normative fMRI data. 
  • Bioavailability of terfenadine in man. 
  • Biological assessment of bisphenol A degradation in water following direct photolysis and UV advanced oxidation. 
  • Biological assessments of a mixture of endocrine disruptors at environmentally relevant concentrations in water following UV/H2O2 oxidation. 
  • Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. 
  • Bisphenol A affects androgen receptor function via multiple mechanisms. 
  • Bisphenol A delays the perinatal chloride shift in cortical neurons by epigenetic effects on the Kcc2 promoter. 
  • Bisphenol A exposure alters developmental gene expression in the fetal rhesus macaque uterus. 
  • Bisphenol A exposure alters placentation and causes preeclampsia-like features in pregnant mice involved in reprogramming of DNA methylation of WNT2. 
  • Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. 
  • Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER. 
  • Building the Foundation for a New Era of Quadruple Therapy in Heart Failure. 
  • Comparisons of polychromatic and monochromatic UV-based treatments of bisphenol-A in water via toxicity assessments. 
  • Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. 
  • Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. 
  • Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. 
  • Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. 
  • Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. 
  • Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. 
  • Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. 
  • Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine? 
  • Decoding the language of epigenetics during neural development is key for understanding development as well as developmental neurotoxicity. 
  • Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. 
  • Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics. 
  • Double-Blind, Placebo-Controlled, Crossover Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia. 
  • Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: a multicenter fMRI study. 
  • Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. 
  • Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. 
  • Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. 
  • Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. 
  • Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. 
  • Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. 
  • Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. 
  • Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. 
  • Empagliflozin in Patients with Chronic Kidney Disease. 
  • Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. 
  • Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. 
  • Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. 
  • Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. 
  • FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? 
  • From the editor: A run of success in treating atherosclerotic vascular disease. 
  • Gene expression in oogenesis and implications for transgenerational effects of environmental toxicants. 
  • Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. 
  • Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. 
  • Good Guys, Bad Guys, Guesses, and Near Misses in Nephrology. 
  • In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status. 
  • Inhibition of thyroid hormone sulfotransferase activity by brominated flame retardants and halogenated phenolics. 
  • Maternal serum bisphenol A levels and risk of pre-eclampsia: a nested case-control study. 
  • Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. 
  • Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. 
  • Multicenter, double-blind, placebo-controlled trial of terfenadine suspension in the treatment of fall-allergic rhinitis in children. 
  • On chronic fatigue syndrome. 
  • Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. 
  • Palladium-catalyzed asymmetric diene cyclization/hydrosilylation employing functionalized silanes and disiloxanes. 
  • Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. 
  • Pediatric narcolepsy. 
  • Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus. 
  • Radioimmunoassay for terfenadine in human plasma. 
  • Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. 
  • Recommendations for high-priority research on cancer-related fatigue in children and adults. 
  • Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. 
  • Reproducibility of adipogenic responses to metabolism disrupting chemicals in the 3T3-L1 pre-adipocyte model system: An interlaboratory study. 
  • Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF". 
  • Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. 
  • Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. 
  • Synthesis of human CCK26-33 and CCK-33 related analogues on 2,4-DMBHA and TMBHA. 
  • Targeting Inhibitor of Apoptosis Proteins Protects from Bleomycin-Induced Lung Fibrosis. 
  • The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures. 
  • The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition. 
  • The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. 
  • The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia. 
  • The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. 
  • The selective metabotropic glutamate receptor 7 allosteric agonist AMN082 inhibits inflammatory pain-induced and incision-induced hypersensitivity in rat. 
  • Toxicology of environmental estrogens. 
  • Transcriptomics integrated with metabolomics reveals the effect of Bisphenol F (BPF) exposure on intestinal inflammation. 
• 

  Keywords of People

  • Gunn, Michael Dee, Professor of Medicine, Integrative Immunobiology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology